[Translation] A single-center, randomized, double-blind, placebo-controlled, multiple-dose, single/multiple-dose phase Ib clinical trial of KW-136 capsules in patients with hepatitis C virus infection

（1）评价KW-136胶囊在丙型肝炎病毒感染者中多剂量、单次/多次给药耐受性；（2）评价KW-136胶囊在丙型肝炎病毒感染者中多剂量、单次/多次给药药代动力学；（3）评价KW-136胶囊在丙型肝炎病毒感染者中多剂量、单次/多次给药的抗病毒活性。

[Translation]

(1) To evaluate the tolerability of KW-136 capsules after multiple doses and single/multiple administrations in patients with HCV infection; (2) To evaluate the pharmacokinetics of KW-136 capsules after multiple doses and single/multiple administrations in patients with HCV infection; (3) To evaluate the antiviral activity of KW-136 capsules after multiple doses and single/multiple administrations in patients with HCV infection.

Start Date23 Nov 2016

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

[+1]

CTR20160467

/ CompletedPhase 1

评价KW-136胶囊在健康受试者中单中心、随机、双盲、安慰剂对照的多剂量单次、多次给药的耐受性、药代动力学及食

[Translation] To evaluate the tolerability, pharmacokinetics and dietary effects of KW-136 capsules in a single-center, randomized, double-blind, placebo-controlled, multiple-dose single-dose and multiple-dose study in healthy subjects.

评价KW-136胶囊在健康受试者中多剂量单次、多次给药的安全性和耐受性，确定最大耐受剂量；在健康受试者中多剂量单次、多次给药药代动力学特征，探讨其在体内吸收、代谢和消除的动态变化特点；食物对健康受试者口服KW-136胶囊药代动力学的影响。为后期临床试验的安全的剂量范围、给药方法、剂量范围和给药方式提供参考依据。

[Translation]

To evaluate the safety and tolerability of single and multiple doses of KW-136 capsules in healthy subjects, and determine the maximum tolerated dose; to evaluate the pharmacokinetic characteristics of single and multiple doses of KW-136 capsules in healthy subjects, and to explore the dynamic changes of its absorption, metabolism and elimination in the body; to evaluate the effect of food on the pharmacokinetics of oral KW-136 capsules in healthy subjects. To provide a reference for the safe dosage range, administration method, dosage range and administration mode of later clinical trials.

Start Date27 Jul 2016

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

[+1]

CTR20170159

/ RecruitingPhase 1

KW-136胶囊与索氟布韦片在健康受试者中单中心、随机、开放、稳态给药的药物相互作用试验

[Translation] A single-center, randomized, open-label, steady-state drug interaction trial between KW-136 capsules and sofosbuvir tablets in healthy subjects

评价KW-136胶囊与索氟布韦片的药物-药物相互作用，以及KW-136胶囊与索氟布韦片联合用药在健康受试者中的药代动力学特性和耐受性，为后续临床试验给药方案设计提供依据。

[Translation]

To evaluate the drug-drug interactions between KW-136 capsules and sofosbuvir tablets, as well as the pharmacokinetic properties and tolerability of the combination of KW-136 capsules and sofosbuvir tablets in healthy subjects, and to provide a basis for the design of dosing regimens in subsequent clinical trials.

Start Date-

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

[+1]

100 Clinical Results associated with China General Nuclear Power Corp.

0 Patents (Medical) associated with China General Nuclear Power Corp.

814

Literatures (Medical) associated with China General Nuclear Power Corp.

01 Aug 2025·NUCLEAR ENGINEERING AND DESIGN

Cavitation-assisted jet decontamination of lead–bismuth eutectic alloy from stainless steel surface with using bionic snapping shrimp’s nozzle

Author: Liu, Feng ; Li, Xuefei ; Zhang, Chen ; Li, Jiawen ; Wang, Cailun ; Zhan, Jie ; Bai, Yunkang ; Heng, Jinlong

The low-melting and high-boiling lead-bismuth eutectic alloy is used in nuclear reactor as heat exchange medium, which causes lead-bismuth eutectic alloy to be adhered on stainless steel surface of nuclear reactor.The current cleaning methods are challenging to remove lead-bismuth eutectic alloy on stainless steel surface with high efficiency and high decontamination effectiveness in an environmentally friendly manner.Thus, a new cavitation-assisted decontamination method with using bionic jet nozzle mapping from snapping shrimp claw is proposed in the paper.Firstly, a new bionic jet nozzle mapping from snapping shrimp claw is designed and manufactured based on the characteristics of cavitation effect generated by the high-speed closure of the claw of snapping shrimp.Secondly, the cavitation-assisted decontamination of lead-bismuth eutectic alloy from stainless steel surface by using the bionic jet nozzle is investigated exptl. and an exptl. platform is established with combining the bionic jet nozzle.Finally, the results of decontamination effectiveness are evaluated from comprehensive score with three indicators, observation of surface microscopic morphol., anal. of water quality for waste liquid, solid impurity anal. 316L stainless steel adhered with lead-bismuth alloy is taken as exptl. samples and the decontamination area ratio, weight reduction rate, and surface roughness Ra of the sample are selected as evaluation indicators of decontamination effect.The weights of each indicator are assigned using the entropy weight method and a comprehensive score of the decontamination effect for each sample is calculated by the above method.The optimal process parameters are determined and validated as nozzle inlet pressure 17.5 MPa, target distance 6 mm, and jet duration 8 min.The average values of the decontamination area ratio, weight reduction rate, and surface roughness Ra of the sample after decontamination under the optimal process parameter are resp. 89.9%, 90.7%, and 0.816μm.The test results of water quality for the waste liquid after decontamination show that the COD of the waste liquid generated by the cavitation-assisted jet decontamination is much lower than the that of chem. immersion decontamination method.This study indicates that the cavitation-assisted jet decontamination method with bionic nozzle mapping from snapping shrimp claw can effectively remove lead-bismuth alloys from the surface of stainless steel and is more environmentally friendly.

01 Jul 2025·NUCLEAR ENGINEERING AND DESIGN

Numerical analysis of a water-LBE interaction experiment: Sensitivity analysis, inverse uncertainty quantification and uncertainty propagation

Author: Mao, Feng ; Wang, Xin′an ; Zhou, Qing

Accurately predicting reactor behavior during Steam Generator Tube Rupture (SGTR) events in Lead-Bismuth Cooled Fast Reactors (LBFRs) is critical for ensuring safety and reliability.This study employs a two-dimensional numerical simulation model to analyze water-LBE interactions during SGTR events with an experiment conducted at the China Nuclear Power Technol. Research Institute (CNPRI).A comprehensive sensitivity anal. identified key input parameters that significantly influence pressure responses within the primary pool.Utilizing the Input Parameter Range Evaluation Methodol. (IPREM), uncertainty ranges for these parameters were systematically determinedMonte Carlo method, guided by Wilks′ formula, propagated these uncertainties to generate uncertainty bands for pressure responses.The simulation results demonstrated that the uncertainty bands effectively encompassed the observed pressure transients, confirming the model′s reliability.

01 Jul 2025·ANNALS OF NUCLEAR ENERGY

Assessing sensitivity and uncertainty in rod ejection accidents: A combined PCE-POD approach

Author: Zhang, Yijun ; He, Qingyun ; Li, Jinggang ; Li, Wenhuai ; ling, Zeng ; Peng, Sitao ; Wang, Tao ; Wang, Ting ; Lu, Haoliang

This study investigates the sensitivity and uncertainty of outcomes related to rod ejection accidents in nuclear reactors, focusing on the impact of perturbations in neutron parameters.By perturbing the macroscopic cross-sections of fuel assemblies, we assess how these variations influence reactor dynamics during transient events.We employ Polynomial Chaos Expansion (PCE) combined with Proper Orthogonal Decomposition (POD) to create an efficient anal. framework for quantifying uncertainty.Using Monte Carlo simulations as a benchmark, we demonstrate that PCE can accurately estimate the mean and variance of global peaking parameters with significantly fewer samples than traditional methods.Our findings reveal that only a limited number of POD modes can capture the majority of the energy distribution, facilitating a more streamlined anal.This research enhances our understanding of reactor behavior under uncertainty and contributes to improving safety assessments in nuclear engineering.

News (Medical) associated with China General Nuclear Power Corp.

28 Feb 2023

·www.prnewswire.com

RaySearch Laboratories: Year-end report 2022

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- "In the fourth quarter of 2022, order intake increased by 49 percent and net sales rose 40 percent. Operating profit amounted to SEK 21 M (-17)." Johan Löf, CEO of RaySearch FOURTH QUARTER (OCTOBER - DECEMBER 2022) Order intake SEK 514.4 M (345.0) Net sales SEK 264.4 M (188.6) Operating profit SEK 20.7 M (-16.6)) Profit after tax SEK 14.1 M (-16.0) Profit per share before/after dilution SEK 0.41 (-0.47) Cash flow SEK 42.8 M (-20.1) Order backlog SEK 1,940.1 M (1,362,9) at the end of the period TWELVE MONTHS (JANUARY - DECEMBER 2022) Order intake SEK 1,218.5 M (807.8) Net sales SEK 843.6 M (641.7) Operating profit SEK 42.7 M (-53.3) Profit after tax SEK 23.8 M (-47.3) Profit per share before/after dilution SEK 0.69 (-1.38) Cash flow SEK 46.8 M (-71.7) SIGNIFICANT EVENTS DURING THE FOURTH QUARTER RaySearch received its largest order ever when Ion Beam Applications S.A. (IBA) placed an order of 17.3 MEUR for RayStation and RayCare for installation at nine proton centers in Spain. University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, in the United States, placed an order for RayStation. CGN Medical Technologies placed an order for RayStation, which CGN sold together with IBA's proton treatment system to Yangzhou Hospital in China. Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) in the United States, placed an order for RayStation. NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD WEBCAST CEO Johan Löf and CFO Henrik Bergentoft will present RaySearch's the year-end report 2022 at a webcast to be held in English on Tuesday, February 28, 2023, at 10:00-10:30 a.m. CET. Link to webcast: You can also join the webcast by phone: Sverige: +46 8 505 583 51 UK: +44 333 300 92 67 US: +1 646 722 49 56 The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 28, 2023, at 7:45 a.m. CET. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected] Henrik Bergentoft, CFO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected] The following files are available for download: SOURCE RaySearch Laboratories

Financial Statement

100 Deals associated with China General Nuclear Power Corp.

100 Translational Medicine associated with China General Nuclear Power Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 05 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Coblopasvir hydrochloride ( NS5A )	Hepatitis C, Chronic More	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

China General Nuclear Power Corp.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 05 Aug 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing